435 related articles for article (PubMed ID: 28254409)
41. Pancreatic cancer: translational research aspects and clinical implications.
Ansari D; Chen BC; Dong L; Zhou MT; Andersson R
World J Gastroenterol; 2012 Apr; 18(13):1417-24. PubMed ID: 22509073
[TBL] [Abstract][Full Text] [Related]
42. Molecular targeted approaches for treatment of pancreatic cancer.
Huang ZQ; Saluja AK; Dudeja V; Vickers SM; Buchsbaum DJ
Curr Pharm Des; 2011; 17(21):2221-38. PubMed ID: 21777178
[TBL] [Abstract][Full Text] [Related]
43. Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them.
Ramos A; Sadeghi S; Tabatabaeian H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502361
[TBL] [Abstract][Full Text] [Related]
44. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.
Li GH; Qu Q; Qi TT; Teng XQ; Zhu HH; Wang JJ; Lu Q; Qu J
J Exp Clin Cancer Res; 2021 May; 40(1):174. PubMed ID: 34011395
[TBL] [Abstract][Full Text] [Related]
45. Role of microRNAs in chemoresistance.
Magee P; Shi L; Garofalo M
Ann Transl Med; 2015 Dec; 3(21):332. PubMed ID: 26734642
[TBL] [Abstract][Full Text] [Related]
46. MicroRNAs: short non-coding players in cancer chemoresistance.
Donzelli S; Mori F; Biagioni F; Bellissimo T; Pulito C; Muti P; Strano S; Blandino G
Mol Cell Ther; 2014; 2():16. PubMed ID: 26056584
[TBL] [Abstract][Full Text] [Related]
47. The role of non-coding RNAs in chemotherapy for gastrointestinal cancers.
Dashti F; Mirazimi SMA; Rabiei N; Fathazam R; Rabiei N; Piroozmand H; Vosough M; Rahimian N; Hamblin MR; Mirzaei H
Mol Ther Nucleic Acids; 2021 Dec; 26():892-926. PubMed ID: 34760336
[TBL] [Abstract][Full Text] [Related]
48. Non-Coding RNAs in Lung Cancer: Contribution of Bioinformatics Analysis to the Development of Non-Invasive Diagnostic Tools.
Kunz M; Wolf B; Schulze H; Atlan D; Walles T; Walles H; Dandekar T
Genes (Basel); 2016 Dec; 8(1):. PubMed ID: 28035947
[TBL] [Abstract][Full Text] [Related]
49. Non-Coding RNAs and the Development of Chemoresistance to Docetaxel in Prostate Cancer: Regulatory Interactions and Approaches Based on Machine Learning Methods.
Pudova E; Kobelyatskaya A; Emelyanova M; Snezhkina A; Fedorova M; Pavlov V; Guvatova Z; Dalina A; Kudryavtseva A
Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137905
[TBL] [Abstract][Full Text] [Related]
50. Editorial: Molecular and cellular mechanisms for cancer therapy resistance.
Battaglia AM; Giorgio E; Petriaggi L; Biamonte F; Momeny M
Front Oncol; 2023; 13():1340318. PubMed ID: 38094612
[No Abstract] [Full Text] [Related]
51. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance.
Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP
Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716
[TBL] [Abstract][Full Text] [Related]
52. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
[TBL] [Abstract][Full Text] [Related]
53. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
54. The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential.
Pandya G; Kirtonia A; Sethi G; Pandey AK; Garg M
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188423. PubMed ID: 32871244
[TBL] [Abstract][Full Text] [Related]
55. Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer.
Xie W; Chu M; Song G; Zuo Z; Han Z; Chen C; Li Y; Wang ZW
Semin Cancer Biol; 2022 Aug; 83():303-318. PubMed ID: 33207266
[TBL] [Abstract][Full Text] [Related]
56. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer.
Xiong G; Pan S; Jin J; Wang X; He R; Peng F; Li X; Wang M; Zheng J; Zhu F; Qin R
Front Oncol; 2021; 11():765216. PubMed ID: 34760707
[TBL] [Abstract][Full Text] [Related]
57. Exosomes in Cancer: Diagnostic and Therapeutic Applications.
Maqsood Q; Sumrin A; Saleem Y; Wajid A; Mahnoor M
Clin Med Insights Oncol; 2024; 18():11795549231215966. PubMed ID: 38249520
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer.
Demiray AG; Demiray A; Yaren A; Yapar Taşköylü B; Gököz Doğu G; Değirmencioğlu S; Çakıroğlu U; Özhan N; Karan C; Çakan Demirel B; Doğan T; Özdemir M
Turk J Gastroenterol; 2022 Aug; 33(8):696-703. PubMed ID: 35943151
[TBL] [Abstract][Full Text] [Related]
59. LINC02418 upregulates EPHA2 by competitively sponging miR-372-3p to promote 5-Fu/DDP chemoresistance in colorectal cancer.
Yao F; Huang X; Xie Z; Chen J; Zhang L; Wang Q; Long H; Jiang J; Wu Q
Carcinogenesis; 2022 Oct; 43(9):895-907. PubMed ID: 35914269
[TBL] [Abstract][Full Text] [Related]
60. CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway.
Zhang Z; Chen L; Zhao C; Gong Q; Tang Z; Li H; Tao J
Cell Biol Toxicol; 2023 Aug; 39(4):1549-1560. PubMed ID: 35913601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
